ASTRAZENECA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10,702.00 GBX | +0.45% |
|
+1.40% | +0.96% |
| 06:00pm | Global markets live: BlackRock, Apple, Comcast, Boeing, Palantir... |  |
| 02:11pm | Astrazeneca Reports Positive Phase 3 Calquence Data for Chronic Lymphocytic Leukemia | MT |
Summary: AstraZeneca PLC
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Highlights: AstraZeneca PLC
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses: AstraZeneca PLC
- With an enterprise value anticipated at 3.54 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company appears highly valued given the size of its balance sheet.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The company's earnings releases usually do not meet expectations.
Ratings Chart: AstraZeneca PLC
Source: Surperformance
ESG chart: AstraZeneca PLC
Source: Refinitiv
| Composite Fundamentals | Composite Valuation | Composite Momentum | Capi. ($) | ||
|---|---|---|---|---|---|
| 211B | |||||
| 744B | |||||
| 493B | |||||
| 359B | |||||
| 311B | |||||
| 261B | |||||
| 235B | |||||
| 205B | |||||
| 147B | |||||
| 146B | |||||
| Average | 311.16B | ||||
| Weighted average by Cap. |
Investor Rating
Trading Rating
ESG Refinitiv
B+
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- AZN Stock
- Ratings AstraZeneca PLC